Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryohei Katayama

Showing results (61-70 of 107) with videos related to

Pageof 11
Sort By:
Cancer Science|January 22, 2020
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanismsNoriko Yanagitani, Ken Uchibori, Sumie Koike, et al.
Cancer Genetics|May 22, 2022
Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancerKatsutoshi Seto, Junichi Shimizu, Katsuhiro Masago, et al.
JCI Insight|November 2, 2023
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGFNobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, et al.
Oncotarget|February 9, 2018
Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitorsYoshimi Ohashi, Mutsumi Okamura, Ryohei Katayama, et al.
The Journal of Experimental Medicine|March 16, 2019
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancerBo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
Molecular and Cellular Biology|September 16, 2004
Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signalingMikihiko Naito, Ryohei Katayama, Toshiyasu Ishioka, et al.
Oncogene|July 24, 2021
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasisSatoshi Takagi, Yuki Sasaki, Sumie Koike, et al.
Molecular Cancer Therapeutics|February 10, 2017
<i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal CancerNoritaka Tanaka, Tetsuo Mashima, Anna Mizutani, et al.
Cancer Science|March 9, 2021
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCRRyo Ariyasu, Ken Uchibori, Takaaki Sasaki, et al.
Acta Biomaterialia|May 27, 2024
In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissuesYuki Takahashi, Rii Morimura, Kei Tsukamoto, et al.
Pageof 11

Showing results (61-70 of 107) with videos related to

Sort By:
Pageof 11
Cancer Science|January 22, 2020
Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanismsNoriko Yanagitani, Ken Uchibori, Sumie Koike, et al.
Cancer Genetics|May 22, 2022
Sensitivity to dabrafenib and trametinib treatments in patients with non-small-cell cancer harboring BRAF compound mutations: A pooled analysis of BRAF p.V600E-positive advanced non-small-cell lung cancerKatsutoshi Seto, Junichi Shimizu, Katsuhiro Masago, et al.
JCI Insight|November 2, 2023
MIG6 loss confers resistance to ALK/ROS1 inhibitors in NSCLC through EGFR activation by low-dose EGFNobuyuki Kondo, Takahiro Utsumi, Yuki Shimizu, et al.
Oncotarget|February 9, 2018
Targeting the Golgi apparatus to overcome acquired resistance of non-small cell lung cancer cells to EGFR tyrosine kinase inhibitorsYoshimi Ohashi, Mutsumi Okamura, Ryohei Katayama, et al.
The Journal of Experimental Medicine|March 16, 2019
Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancerBo Gong, Kazuma Kiyotani, Seiji Sakata, et al.
Molecular and Cellular Biology|September 16, 2004
Cellular FLIP inhibits beta-catenin ubiquitylation and enhances Wnt signalingMikihiko Naito, Ryohei Katayama, Toshiyasu Ishioka, et al.
Oncogene|July 24, 2021
Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasisSatoshi Takagi, Yuki Sasaki, Sumie Koike, et al.
Molecular Cancer Therapeutics|February 10, 2017
<i>APC</i> Mutations as a Potential Biomarker for Sensitivity to Tankyrase Inhibitors in Colorectal CancerNoritaka Tanaka, Tetsuo Mashima, Anna Mizutani, et al.
Cancer Science|March 9, 2021
Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCRRyo Ariyasu, Ken Uchibori, Takaaki Sasaki, et al.
Acta Biomaterialia|May 27, 2024
In vitro throughput screening of anticancer drugs using patient-derived cell lines cultured on vascularized three-dimensional stromal tissuesYuki Takahashi, Rii Morimura, Kei Tsukamoto, et al.
Pageof 11